Vittoriabio
Philadelphia, US · Founded 2021 · 3 known investors
Find your way into Vittoriabio
24 people in our graph share verified history with the Vittoriabio team — schools, employers, funds. One of them is your warm intro.
Brian Halakunlockedknows Nicholas Siciliano · together at Thomas Jefferson University
×11knows the team · via Thomas Jefferson University
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types. The company focuses on expanding the scope and efficacy of CAR T-cell treatment for patients with limited therapeutic options.
Founders & leadership
Vittoriabio was founded in 2021 by Nicholas Siciliano.
NS
Nicholas SicilianoinFounder · Chief Executive OfficerNicholas Siciliano is Chief Executive Officer of ViTToria Biotherapeutics, a gene-edited cell therapy company, and previously co-founded and led Invisible Sentinel as CEO from 2013 to 2021. An immunologist with over two decades of experience in immunology, microbiology, molecular biology, and therapeutics development, he has held roles spanning commercial strategy, R&D, and business development.
PN
Preston NoonExecutive
Board
GV
Geeta VemuriBoard director
BP
Bruce PeacockBoard director
LM
Leon MoulderBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$8.7M disclosed across 1 round · 2021
▶$8.7MraisedDec 2021 · 11 investors · BiotechnologyRule 506(b)
▶$8.7MraisedDec 2021 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Preston NoonExecutive Officer
- Geeta VemuriExecutive Officer, Director
- Nicholas SicilianoDirector
- Bruce PeacockExecutive Officer, Director
- Leon MoulderDirector
- Offering amount
- $9.2M
- Amount sold
- $8.7M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vittoriabio do?
- Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types. The company focuses on expanding the scope and efficacy of CAR T-cell treatment for patients with limited therapeutic options.
- Who founded Vittoriabio?
- Vittoriabio was founded by Nicholas Siciliano in 2021.
- Who are Vittoriabio's investors?
- Vittoriabio's investors include Agent Capital, BioAdvance, Global BioAccess Fund.
- How much funding has Vittoriabio raised?
- Vittoriabio has disclosed $8.7M raised across 1 round.
- Where is Vittoriabio headquartered?
- Vittoriabio is headquartered in Philadelphia, US.